Results 61 to 70 of about 10,572,916 (223)

Nutrient/TOR signaling controls adipose mitochondrial transcription factor A (TFAM) to regulate organismal growth in Drosophila

FEBS Letters, EarlyView.
Animals must match their growth rate to available nutrients. We show that in Drosophila larvae, the nutrient‐sensing TOR kinase controls growth by regulating levels of TFAM, a key regulator of mitochondrial function, in the adipose tissue. When nutrients are abundant, high TOR activity suppresses TFAM, lowering mitochondrial bioenergetic activity and ...
Shrivani Sriskanthadevan‐Pirahas, Shahoon Khan, Abhishek Sharma, Byoungchun Lee, Savraj S. Grewal   +4 more
wiley   +1 more source

Characteristics of responders and non-responders.

, 2017
Characteristics of responders and non-responders.
Sang Joon An (3829756), Sang-Bae Ko (3829765), Kyungmi Oh (3829768), Moon-Ku Han (396939), Byung-Woo Yoon (3829762), Chi Kyung Kim (286848), Tae Jung Kim (3829750), Heejung Mo (2509726), Ki-Woong Nam (3829753), Min Kyoung Kang (3829759), Andrew M. Demchuk (425292)   +10 more
core   +1 more source

Clinical characteristics of PIVKA-Ⅱ responders and non-responders.

, 2022
Clinical characteristics of PIVKA-Ⅱ responders and non-responders.
Shun Kaneko (8735283), Chiaki Maeyashiki (749428), Tsubasa Nobusawa (12225733), Kaoru Tsuchiya (793697), Kento Inada (8735286), Masayuki Kurosaki (156560), Yuka Takahashi (172894), Tatsuya Kakegawa (12225736), Kenta Takaura (1807024), Namiki Izumi (156627), Shohei Tanaka (495440), Hiroyuki Nakanishi (698666), Yuki Tanaka (112000), Sakura Kirino (8735280), Yuka Hayakawa (675583), Yutaka Yasui (33074), Hiroaki Matsumoto (9077741), Shun Ishido (12225730), Koji Yamashita (3063837), Nobuharu Tamaki (793693), Mayu Higuchi (793694)   +20 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Comparison between responders and non-responders.

, 2018
Comparison between responders and non-responders.
David Armstrong (109098), Jennie Hejdenberg (5130755), Ben Morgan (5130752), Saba Hinrichs-Krapels (5130758)   +3 more
core   +1 more source

Table_1_HIV-Sheltering Platelets From Immunological Non-Responders Induce a Dysfunctional Glycolytic CD4+ T-Cell Profile.xlsx

, 2022
Immunological non-responders (InRs) are HIV-infected individuals in whom the administration of combination antiretroviral therapy (cART), although successful in suppressing viral replication, cannot properly reconstitute patient circulating CD4+ T-cell ...
Aiwei Zhu (12075422), Pierre de Truchis (323395), Ségolène Greffe (12075425), Elisabeth Rouveix (308408), Claude Capron (5679248), Morgane Bomsel (81994), Fernando Real (185142), Jaja Zhu (10180913)   +7 more
core   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Survival comparison between responders and non-responders.

, 2020
Responders (n = 45, decrease in T1Gd volume during adjuvant TMZ) had significantly longer overall survival than non-responders (n = 45, increase in T1Gd volume during adjuvant TMZ).
Sujay Vora (8630097), Susan Christine Massey (4809816), Haylye White (8630076), Pamela R. Jackson (8630088), Leland S. Hu (8630100), Sandra K. Johnston (8496303), Bernard R. Bendok (8630091), Kristin R. Swanson (8496309), Paula Whitmire (8630079), Jann N. Sarkaria (238863), Kyle W. Singleton (8630085), Tatum Doyle (8630082), Alyx B. Porter (8630094), Andrea Hawkins-Daarud (4809819), Maciej M. Mrugala (8630103)   +14 more
core   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Comparison of responders and non-responders.

, 2016
Comparison of responders and non-responders.
Imed Harrabi (2580121), Zouhair Tabka (2580115), Hager Daldoul (2580112), Louisa Gnatiuc (2580109), Meriam Denguezli (2580118), Peter Burney (59835), Sonia Coton (2580106)   +6 more
core   +1 more source